A large real-world study published in Nature Medicine demonstrates that GLP-1 receptor agonists—specifically semaglutide and tirzepatide—significantly reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes.
The research, which benchmarked real-world evidence against randomized clinical trial data, provides robust confirmation that these medications offer substantial cardiovascular protection beyond their glucose-lowering and weight-management benefits. The findings support broader use of GLP-1 therapies for cardiovascular risk reduction in routine clinical practice.
Study Design and Data Sources
Researchers conducted five emulated trials using three major U.S. claims databases: Medicare Parts A, B, and D (2018-2020), Optum Clinformatics Data Mart (2018-February 2025), and Merative MarketScan (2018-2023).
These datasets provided de-identified longitudinal information on diagnoses, prescriptions, procedures, and healthcare utilization across diverse populations. The study followed a three-phase approach: replicating SUSTAIN-6 and SURPASS-CVOT trials, expanding to real-world cohorts, and directly comparing tirzepatide versus semaglutide.
Participant Profile and Methodological Rigor
The study included adults with type 2 diabetes and obesity, stratified by cardiovascular risk factors including established cardiovascular disease, NYHA class II-III heart failure, or chronic kidney disease.
Researchers used propensity score matching (1:1, caliper 0.01) to balance treatment groups and employed Kaplan-Meier curves, Cox proportional hazards models, and fixed-effects meta-analysis. The RCT-DUPLICATE framework ensured methodological consistency with benchmark trials.
Key Efficacy Findings
The analysis revealed significant cardiovascular benefits:
Semaglutide vs. sitagliptin: Reduced 1-year risk of myocardial infarction or stroke (1.5% vs. 1.7%; HR 0.82, 95% CI 0.74–0.91)
Tirzepatide vs. dulaglutide: Lower MACE risk (1.4% vs. 1.8%; HR 0.87, 95% CI 0.75–1.01)
Head-to-head comparison: Tirzepatide and semaglutide showed comparable cardiovascular outcomes (HR 1.06, 95% CI 0.95–1.18)
Secondary outcomes favored GLP-1 agonists for reducing heart failure hospitalizations and emergency visits.
Validation Against Clinical Trials
Benchmark analyses showed strong concordance with reference trials. The SURPASS-CVOT simulation yielded a MACE hazard ratio of 0.83 (95% CI 0.69–1.01) versus 0.92 (95% CI 0.83–1.01) in the actual trial, meeting all consistency criteria.
Similarly, SUSTAIN-6 simulation reproduced trial-aligned estimates, though all-cause mortality showed potential residual confounding, leading to methodological refinements focusing on myocardial infarction and stroke endpoints.
Clinical Implications and Future Directions
“These real-world findings reinforce that GLP-1 receptor agonists provide meaningful cardiovascular protection beyond glucose control,” stated the research team.
The results support broader implementation of these therapies in routine care for type 2 diabetes patients with cardiovascular risk factors. Future research should address claims data limitations regarding behavioral and clinical details while exploring long-term outcomes across diverse patient populations.
Related topics:
